Who is sponsoring SMART-DECISION?

SMART-DECISION is sponsored by Samsung Medical Center.

What condition does SMART-DECISION study?

SMART-DECISION studies Myocardial Infarction.

What drugs are being tested in SMART-DECISION?

Interventions: Discontinuation of β-blocker.

What is the status of SMART-DECISION?

SMART-DECISION is currently RECRUITING.

Last reviewed 2025-12-29 · How we verify

Long-term Beta-blocker Therapy After Acute Myocardial Infarction (SMART-DECISION)

NCT04769362 PHASE4 RECRUITING

The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI). Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.

Details

Lead sponsor	Samsung Medical Center
Phase	PHASE4
Status	RECRUITING
Enrolment	2540
Start date	Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Myocardial Infarction

Interventions

Discontinuation of β-blocker

Countries

South Korea